Clinical trials: Cerebrovascular Disorder
Stroke, Muscle Spasticity
Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function
The purpose of this study is to evaluate the safety of injections of botulinum toxin Type A in patients with reduced lung function and focal upper limb poststroke spasticity
- Conditions
- Stroke, Muscle Spasticity, Motor Neuron Disease
- Trial name
- NCT00076687
- Testing
- botulinum toxin Type A, saline
- Where
- 4 sites in United States, Czechia and 2 more
- Volunteers
- 155 people
- Sponsor
- Allergan
Ischemic Stroke
A Study of the Safety, Imaging and Clinical Outcomes of THR-18 in Acute Stroke Subjects Treated With tPA
This study will test the experimental drug "THR-18" given together with the drug "tissue plasminogen activator" for the treatment of stroke. Tissue plasminogen activator is also called "tPA".
- Trial name
- NCT02572336
- Testing
- THR-18, Tissue Plasminogen Activator (tPA)
- Where
- Moldova
- Volunteers
- 40 people
- Sponsor
- D-Pharm Ltd.
Aneurysmal Subarachnoid Hemorrhage
Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping
The aim of this study is to demonstrate that clazosentan, administered as a continuous intravenous infusion at 5 mg/h until Day 14 post aneurysmal subarachnoid hemorrhage (aSAH), reduces the incidence of cerebral vasospasm…
- Trial name
- CONSCIOUS-2 (NCT00558311)
- Testing
- Clazosentan
- Where
- 117 sites in United States, Australia and 27 more
- Volunteers
- 1,157 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Acute Ischemic Stroke
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
This study tests the drug, Plasmin (Human), in patients with a stroke due to a clot in the middle cerebral artery (MCA). Plasmin is an enzyme that causes clot lysis by cleaving a clot component, fibrin.
- Trial name
- NCT01014975
- Testing
- Plasmin (Human)
- Where
- 23 sites in Australia, Austria and 4 more
- Volunteers
- 40 people
- Sponsor
- Grifols Therapeutics LLC
Cerebral Infarction
The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction
The purposes of the study is to determine the safety and efficacy of treating acute ischemic stroke patients with human umbilical cord mesenchymal stem cells (hUC-MSC).
- Trial name
- NCT03186456
- Testing
- Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#), Aspirin Tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Ischemic Stroke
Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke
The purpose of this study is to evaluate the efficacy and safety of intravenous doses of 3K3A-APC, a recombinant variant of human activated protein C (APC), in the treatment of acute ischemic stroke following treatment with…
- Trial name
- RHAPSODY-2 (NCT05484154)
- Testing
- 3K3A-APC
- Sponsor
- ZZ Biotech, LLC
Stroke
Evaluation of the Benefit of the H'Ability Home Device Used in Supervised Self-rehabilitation at Home on the Autonomy of Post-stroke Patients
The goal of this clinical investigation is to evaluate the benefit of the H'Ability Home device used in supervised self-rehabilitation at home on the autonomy of post-stroke patients.
- Trial name
- NCT07202520
- Testing
- IVR : H'Ability Home, Control: paper-based exercise guide
- Where
- 5 sites in France
- Volunteers
- 44 people
- Sponsor
- H'ability
Stroke
An International Observational Study of the Safety and Efficacy of Thrombolysis in Stroke
Study to evaluate the safety and efficacy of intravenous recombinant tissue Plasminogen Activator, alteplase, Actilyse® (rt-PA) (0.9 mg/kg) within 3 hours of symptom onset in acute ischemic stroke
- Trial name
- NCT02229890
- Testing
- alteplase
- Volunteers
- 593 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke
A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)
Evaluation of the safety and tolerability of escalating doses of NR1 administered intracerebrally at a single time-point post-injury to subjects with chronic ISS with or without cortical stroke.
- Trial name
- NCT04631406
- Testing
- Neural Stem Cells
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Clarion Cells, Inc.
Cardiovascular Disease and Lipoprotein(a)
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
- Trial name
- NCT07517263
- Testing
- Pelacarsen (TQJ230)
- Where
- 646 sites in United States, Argentina and 38 more
- Volunteers
- 5,700 people
- Sponsor
- Novartis Pharmaceuticals
Stroke
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
The present study is to be conducted based on the AIS patient data collected from CNSR I, II, and III. The primary objectives are: To investigate the temporal changes in the proportion of intravenous recombinant plasminogen…
- Trial name
- NCT04290494
- Testing
- IV rtPA (intravenous recombinant plasminogen activator)
- Where
- China
- Volunteers
- 42,188 people
- Sponsor
- Boehringer Ingelheim
Carotid Artery Disease
Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial
Evaluate the safety and efficacy of the Protege Stent and Spider Device in the treatment of common and/or internal carotid artery stenoses for subjects that are high risk for carotid endarterectomy.
- Trial name
- CREATE (NCT00619775)
- Testing
- PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device
- Where
- 31 sites in United States
- Volunteers
- 419 people
- Sponsor
- Medtronic Endovascular
Acute Ischemic Stroke
Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial
The primary study objective is to determine if subjects experiencing an acute ischemic stroke due to large vessel occlusion, treated with combined IV t-PA and Solitaire Revascularization Device within 6 hours of symptom onset…
- Trial name
- SWIFT PRIME (NCT01657461)
- Testing
- Intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Solitaire revascularization device
- Where
- United States
- Volunteers
- 196 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Muscle Spasticity, Stroke
Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity
This is a multi-center, randomized, double-blind (patient and evaluator), sham-controlled study to be conducted in stroke patients with upper-extremity spasticity.
- Trial name
- RECOVER (NCT04742257)
- Testing
- MyoRegulator® device
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- PathMaker Neurosystems Inc.
Fabry Disease
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)
This was an open-label study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of migalastat treatment in pediatric participants 12 to <18 years of age with Fabry disease and amenable gene…
- Trial name
- NCT03500094
- Testing
- Migalastat HCl 150 mg
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 22 people
- Sponsor
- Amicus Therapeutics
Intracranial Arteriosclerosis, Stenosis Artery
A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China
The primary objective of this trial is to evaluate the long-term safety and efficacy of the NOVA intracranial drug-eluting stent system in "real world" patients with intracranial atherosclerotic stenosis.
- Conditions
- Intracranial Arteriosclerosis, Stenosis Artery, Drug-Eluting Stents, Intracranial Artery Stenosis
- Trial name
- NCT05692882
- Testing
- Drug-Eluting Stents
- Where
- 5 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Cerebral Palsy, Multiple Sclerosis
The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes
The objective is to explore the potential short and long-term impact of the EXOPULSE Mollii Suit and EXOPULSE Suit on subjects with CP, MS, stroke, fibromyalgia or other neurologic disorders which may cause such types of…
- Conditions
- Cerebral Palsy, Multiple Sclerosis, Stroke, Neurologic Disorder
- Trial name
- EXOREG (NCT05901259)
- Testing
- EXOPULSE Mollii Suit and EXOPULSE Suit
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Otto Bock Healthcare Products GmbH
Cerebrovascular Accident
Study of Hand Therapy 3 to 24 Months After Stroke
The primary aim of this study is to investigate the effectiveness of the use of a robotic hand therapy device in the home environment.
- Trial name
- NCT00435617
- Testing
- Hand Mentor
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Kinetic Muscles
Giant Cell Arteritis
KPL-301 for Subjects With Giant Cell Arteritis
The primary objective of the study is to evaluate the efficacy of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new…
- Trial name
- NCT03827018
- Testing
- mavrilimumab, prednisone
- Where
- 49 sites in United States, Australia and 13 more
- Volunteers
- 70 people
- Sponsor
- Kiniksa Pharmaceuticals, Ltd.
Intracerebral Hemorrhage (ICH)
Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage
This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single escalating dose and repeated doses of CN-105 in healthy adult participants. There will be about 48 subjects, 36 active and 12 placebo.
- Trial name
- NCT02670824
- Testing
- CN-105
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AegisCN LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.